Flinton Capital Management LLC decreased its position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 20.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,328 shares of the biopharmaceutical company’s stock after selling 1,392 shares during the quarter. Flinton Capital Management LLC’s holdings in Esperion Therapeutics were worth $248,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Spark Investment Management LLC lifted its position in Esperion Therapeutics by 72.1% in the first quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock valued at $15,694,000 after purchasing an additional 163,800 shares during the period. Wasatch Advisors Inc. lifted its position in shares of Esperion Therapeutics by 13.4% during the 1st quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock valued at $25,607,000 after acquiring an additional 75,165 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Esperion Therapeutics by 73.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 140,825 shares of the biopharmaceutical company’s stock valued at $6,875,000 after acquiring an additional 59,425 shares during the period. Canada Pension Plan Investment Board lifted its position in shares of Esperion Therapeutics by 17,219.5% during the 2nd quarter. Canada Pension Plan Investment Board now owns 54,210 shares of the biopharmaceutical company’s stock valued at $2,522,000 after acquiring an additional 53,897 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in shares of Esperion Therapeutics by 13.6% during the 1st quarter. Pictet Asset Management Ltd. now owns 437,518 shares of the biopharmaceutical company’s stock valued at $17,566,000 after acquiring an additional 52,467 shares during the period.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben acquired 2,500 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was acquired at an average price of $35.25 per share, with a total value of $88,125.00. Following the transaction, the chief executive officer now directly owns 76,015 shares in the company, valued at $2,679,528.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Target N. V. Biotech bought 80,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the transaction, the insider now owns 3,652,964 shares in the company, valued at approximately $123,397,123.92. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 142,500 shares of company stock valued at $5,291,825. Insiders own 7.70% of the company’s stock.
Shares of Esperion Therapeutics stock opened at $37.78 on Friday. Esperion Therapeutics Inc has a twelve month low of $33.13 and a twelve month high of $60.99. The company has a current ratio of 5.65, a quick ratio of 5.65 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -5.01 and a beta of 1.71. The company has a fifty day moving average price of $36.89 and a 200 day moving average price of $43.56.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($0.15). The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.05 million. Esperion Therapeutics’s quarterly revenue was up 9720.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.71) EPS. Analysts forecast that Esperion Therapeutics Inc will post -3.02 earnings per share for the current year.
Several brokerages recently issued reports on ESPR. BidaskClub downgraded Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 31st. ValuEngine downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Goldman Sachs Group upgraded Esperion Therapeutics from a “sell” rating to a “neutral” rating and cut their price objective for the stock from $55.00 to $45.00 in a research report on Monday, September 16th. Northland Securities restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Finally, Cowen reaffirmed a “buy” rating and issued a $80.00 target price on shares of Esperion Therapeutics in a research note on Thursday, July 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $69.73.
Esperion Therapeutics Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: After-Hours Trading
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.